<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573754</url>
  </required_header>
  <id_info>
    <org_study_id>FDA-2604</org_study_id>
    <secondary_id>R01FD002604</secondary_id>
    <nct_id>NCT01573754</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda</brief_title>
  <official_title>A Prospective Comparison of Low Dose Hydroxychloroquine and Phlebotomy in the Treatment of Porphyria Cutanea Tarda. IRB 02-435</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Porphyria cutanea tarda (PCT) is an iron-related disorder that responds to treatment by&#xD;
      phlebotomy or low-dose hydroxychloroquine, but comparative data on these treatments are&#xD;
      limited. The hypothesis is that hydroxychloroquine is noninferior to phlebotomy in terms of&#xD;
      time to remission. Patients with well documented PCT are assigned to treatment by&#xD;
      randomization if specific criteria are met. All patients are followed until remission -&#xD;
      defined as achieving a normal plasma porphyrin concentration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Pragmatic Interventional study&#xD;
&#xD;
      Primary Study Objective: To determine and compare time to remission with treatment with&#xD;
      low-dose hydroxychloroquine or repeated phlebotomy in participants with PCT.&#xD;
&#xD;
      Secondary Study Objective(s):&#xD;
&#xD;
        1. To assess the effects of susceptibility factors on responses to treatment of PCT by&#xD;
           these methods.&#xD;
&#xD;
        2. To determine and compare rates of recurrence of PCT after treatment with low-dose&#xD;
           hydroxychloroquine or phlebotomy.&#xD;
&#xD;
      Study Population and Main Eligibility/ Exclusion Criteria:&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      Hydroxychloroquine 100 mg twice weekly for up to 24 months by mouth vs. phlebotomy 450 mL&#xD;
      biweekly until target serum ferritin reached, or up to 24 months.&#xD;
&#xD;
      Safety Issues-&#xD;
&#xD;
      1. Side effects of phlebotomy or hydroxychloroquine, which are the same as in clinical&#xD;
      practice.&#xD;
&#xD;
      Primary Outcome Measures:&#xD;
&#xD;
        1. Time to achievement of a normal plasma total porphyrin level.&#xD;
&#xD;
        2. Tolerability and safety of both treatments&#xD;
&#xD;
      Secondary Outcome Measures:&#xD;
&#xD;
        1. Time to disappearance of a plasma fluorescence peak at neutral pH.&#xD;
&#xD;
        2. Time to normalization of urinary total porphyrins.&#xD;
&#xD;
        3. Time to normalization of the urinary total porphyrin pattern by HPLC&#xD;
&#xD;
        4. Effects of susceptibility factors such as hepatitis C, inherited UROD deficiency, etc.&#xD;
           on efficacy and safety of the two treatment methods.&#xD;
&#xD;
        5. Rates of recurrence after each type of treatment and the effects of susceptibility&#xD;
           factors on recurrence rates.&#xD;
&#xD;
      Statistical Considerations (sample size and analysis plan): Time to achieving biochemical&#xD;
      endpoints will be determined from individual subject data. Outcome measures such as time to&#xD;
      remission will be compared using Cox proportional models to study the effects of&#xD;
      susceptibility factors on the hazard ratio to compare the two treatments. Additional modeling&#xD;
      will assess factors affecting the frequency of recurrence and seasonality effects using&#xD;
      logistic regression modeling and log-rank testing, respectively.&#xD;
&#xD;
      Sponsors: National Institutes of Health (NIH)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 21, 2006</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Actual">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma porphyrin concentration</measure>
    <time_frame>6 months</time_frame>
    <description>Upper normal limit - 9 mcg/dL or less</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Porphyria Cutanea Tarda</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-dose hydroxychloroquine 100 mg by mouth twice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phlebotomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phlebotomy 450 mL biweekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>100 mg by mouth twice weekly</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phlebotomy</intervention_name>
    <description>450 mL every 2 weeks</description>
    <arm_group_label>Phlebotomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented porphyria cutanea tarda (PCT)&#xD;
&#xD;
          -  Willing to give informed consent&#xD;
&#xD;
          -  Age 18 or greater&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Blistering skin lesions due to another condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl E Anderson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 5, 2012</study_first_submitted>
  <study_first_submitted_qc>April 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2012</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Porphyria, rare disease, orphan disease, iron metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Porphyria Cutanea Tarda</mesh_term>
    <mesh_term>Porphyrias, Hepatic</mesh_term>
    <mesh_term>Porphyria, Erythropoietic</mesh_term>
    <mesh_term>Porphyrias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Through a NIH data repository at some future time.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

